Literature DB >> 20637264

Autophagy is a therapeutic target in anticancer drug resistance.

Suning Chen1, Sumaiyah K Rehman, Wei Zhang, Aidong Wen, Libo Yao, Jian Zhang.   

Abstract

Autophagy is a type of cellular catabolic degradation response to nutrient starvation or metabolic stress. The main function of autophagy is to maintain intracellular metabolic homeostasis through degradation of unfolded or aggregated proteins and organelles. Although autophagic regulation is a complicated process, solid evidence demonstrates that the PI3K-Akt-mTOR, LKB1-AMPK-mTOR and p53 are the main upstream regulators of the autophagic pathway. Currently, there is a bulk of data indicating the important function of autophagy in cancer. It is noteworthy that autophagy facilitates the cancer cells' resistance to chemotherapy and radiation treatment. The abrogation of autophagy potentiates the re-sensitization of therapeutic resistant cancer cells to the anticancer treatment via autophagy inhibitors, such as 3-MA, CQ and BA, or knockdown of the autophagy related molecules. In this review, we summarize the accumulation of evidence for autophagy's involvement in mediating resistance of cancer cells to anticancer therapy and suggest that autophagy might be a potential therapeutic target in anticancer drug resistance in the future.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637264     DOI: 10.1016/j.bbcan.2010.07.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  132 in total

1.  Silibinin negatively contributes to primary cilia length via autophagy regulated by histone deacetylase 6 in confluent mouse embryo fibroblast 3T3-L1 cells.

Authors:  Qian Xu; Wei Liu; Xiaoling Liu; Weiwei Liu; Hongju Wang; Guodong Yao; Linghe Zang; Toshihiko Hayashi; Shin-Ichi Tashiro; Satoshi Onodera; Takashi Ikejima
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

2.  High CHMP4B expression is associated with accelerated cell proliferation and resistance to doxorubicin in hepatocellular carcinoma.

Authors:  Baoying Hu; Dawei Jiang; Yuyan Chen; Lixian Wei; Shusen Zhang; Fengbo Zhao; Runzhou Ni; Cuihua Lu; Chunhua Wan
Journal:  Tumour Biol       Date:  2015-02-11

Review 3.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

4.  FSIP1 regulates autophagy in breast cancer.

Authors:  Caigang Liu; Lisha Sun; Jie Yang; Tong Liu; Yongliang Yang; Se-Min Kim; Xunyan Ou; Yining Wang; Li Sun; Mone Zaidi; Maria I New; Tony Yuen; Qiyong Guo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

5.  Resilience of death: intrinsic disorder in proteins involved in the programmed cell death.

Authors:  Z Peng; B Xue; L Kurgan; V N Uversky
Journal:  Cell Death Differ       Date:  2013-06-14       Impact factor: 15.828

Review 6.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

7.  Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Authors:  Aaron T Wecksler; Sung Hee Hwang; Hiromi I Wettersten; Jennifer E Gilda; Amy Patton; Leonardo J Leon; Kermit L Carraway; Aldrin V Gomes; Keith Baar; Robert H Weiss; Bruce D Hammock
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

Review 8.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

9.  Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.

Authors:  Yuxia Cui; Stela S Palii; Cynthia L Innes; Richard S Paules
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Authors:  Huiyu Ren; Nicole A Bakas; Mitchell Vamos; Apirat Chaikuad; Allison S Limpert; Carina D Wimer; Sonja N Brun; Lester J Lambert; Lutz Tautz; Maria Celeridad; Douglas J Sheffler; Stefan Knapp; Reuben J Shaw; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2020-11-17       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.